SCHEMBL3137707

SCHEMBL3137707

C[C@@H](C(=O)O)c1ccccc1Nc1c(Cl)cccc1Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCL8 P10145 8/20 1.00
PTGS2 P35354 7/20 0.52
TTR P02766 5/20 0.52
PTGS1 P23219 3/20 0.52
AKR1B10 O60218 2/20 0.52
ABCB11 O95342 2/20 0.52
MT-CO2 P00403 2/20 0.52
ADRA1A P35348 2/20 0.52
UGT1A9 O60656 1/20 0.52
TRPA1 O75762 1/20 0.52
ALB P02768 1/20 0.52
UGT1A6 P19224 1/20 0.52
UGT1A1 P22309 1/20 0.52
CXCR1 P25024 1/20 0.52
AGTR2 P50052 1/20 0.52
NR1I3 Q14994 1/20 0.52
SLC22A6 Q4U2R8 1/20 0.52
NR1H4 Q96RI1 1/20 0.52
UGT1A7 Q9HAW7 1/20 0.52
UGT1A10 Q9HAW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3151521 1.00 CXCL8 (1.00) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL12129515 1.00 CXCL8 (1.00) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL7126780 0.90 CXCL8 (0.82) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL10992714 0.85 CXCL8 (0.73) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL11403823 0.84 CXCL8 (0.73) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL7716835 0.84 CXCL8 (0.73) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL11435906 0.83 CXCL8 (0.71) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL28809681 0.83 CXCL8 (0.71) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL6931840 0.82 CXCL8 (0.69) CXCL8PTGS2TTRPTGS1AKR1B10
SCHEMBL13186033 0.81 CXCL8 (0.68) CXCL8PTGS2TTRPTGS1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2229942-B1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPE SPA (IT) 2012-08-29 EP claimed
EP-2229942-A1 2-Aryl-propionic acids and pharmaceutical compositions containing them Dompe S.p.A. (IT) 2010-09-22 EP claimed
EP-2229942-B1 2-Aryl-propionic acids and pharmaceutical compositions containing them DOMPE SPA (IT) 2012-08-29 EP disclosed
US-8063242-B2 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion DOMPE PHA.R.MA S.P.A. (IT) 2011-11-22 US disclosed
US-8063242-B2 for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion DOMPE PHA.R.MA S.P.A. (IT) 2011-11-22 US disclosed
US-7705050-B2 Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2010-04-27 US disclosed
EP-1255726-B1 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS DOMPE PHA R MA SPA RES & MFG (IT) 2009-11-11 EP disclosed
US-20080045522-A1 OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS DOMPE PHA.R.MA S.P.A. (IT) 2008-02-21 US disclosed
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils DOMPÉ FARMACEUTICI S.P.A. (IT) 2004-09-16 US disclosed
EP-1455773-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Dompé S.P.A. (IT) 2004-09-15 EP disclosed
WO-2003043625-A1 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM DOMPE S.P.A. (IT) 2003-05-30 WO disclosed
EP-1255726-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.P.A. (IT) 2002-11-13 EP disclosed
WO-2001058852-A2 (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS Dompé S.p.A. (IT) 2001-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181073-A1 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils CXCL8, MMP8, CCR8 CXCL8 1/4885PTGS2 219/4885TTR 2843/4885
US-20080045522-A1 OMEGA-AMINOALKYLAMIDES OF R-2-ARYL-PROPIONIC ACIDS AS INHIBITORS OF THE CHEMOTAXIS OF POLYMORPHONUCLEATE AND MONONUCLEATE CELLS C5AR2, C3AR1, C5AR1 CXCL8 49/4885PTGS2 296/4885TTR 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.